ANDA 219714, held by Novitium Pharma. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 219714 (Sertraline Hydrochloride), held by Novitium Pharma, was first approved by FDA on Jan 20, 2026, with 0 approved supplements and 0 published complete response letters.
Sertraline Hydrochloride (HCl) Capsules is indicated for the treatment of the following: Major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) in adults and pediatric patients 6 years and older Sertraline Hydrochloride (HCl) Capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of: Major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) in adults and pediatric patients 6 years and older
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 20, 2026 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 150MG BASE · capsule;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 200MG BASE · capsule;oral | Sertraline Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters